<p>Corient Private Wealth LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在查尔斯河实验室国际公司（NYSE:CRL - 免费报告）的股份增加了 129.3%。该机构投资者在本季度额外收购了 6,669 股后，持有该医疗研究公司 11,825 股股票。根据其最近的 SEC 文件，Corient Private Wealth LLC 在查尔斯河实验室国际的持股价值为 1,794,000 美元。</p>
<ul>
<li>今年迄今表现最差的两只 S&amp;P 500 股票：买入、卖出还是回避？</li>
</ul>
<p>其他一些机构投资者最近也买卖了该股票的股份。Exchange Traded Concepts LLC 在第二季度将其在查尔斯河实验室国际的股份增加了 1.3%。Exchange Traded Concepts LLC 目前持有 5,742 股该医疗研究公司的股票，价值 871,000 美元，此前在上个季度购买了额外的 76 股。Brooklyn Investment Group 在第一季度将其在查尔斯河实验室国际的持股增加了 93.5%。Brooklyn Investment Group 目前持有 178 股该医疗研究公司的股票，价值 27,000 美元，此前在上个季度购买了额外的 86 股。DekaBank Deutsche Girozentrale 在第二季度将其在查尔斯河实验室国际的持股增加了 1.2%。DekaBank Deutsche Girozentrale 目前持有 7,142 股该医疗研究公司的股票，价值 1,072,000 美元，此前在此期间额外收购了 86 股。WESCAP Management Group Inc. 在第二季度将其在查尔斯河实验室国际的股份增加了 3.8%。WESCAP Management Group Inc. 目前持有 2,443 股该医疗研究公司的股票，价值 371,000 美元，此前在上个季度额外收购了 89 股。最后，新泽西州共同养老金基金 D 在第二季度将其在查尔斯河实验室国际的持股增加了 0.7%。新泽西州共同养老金基金 D 目前持有 16,829 股该医疗研究公司的股票，价值 2,553,000 美元，此前在此期间额外收购了 109 股。当前 98.91% 的股票由机构投资者和对冲基金持有。</p>
<h2>查尔斯河实验室国际股票表现</h2>
<p>CRL 周三开盘价为 202.99 美元。该公司的 50 日移动平均价格为 181.14 美元，200 日移动平均价格为 166.54 美元。查尔斯河实验室国际公司的一年最低价为 91.86 美元，一年最高价为 204.47 美元。该股票的市值为 99.9 亿美元，市盈率为 -130.12，市盈增长比率为 7.17，贝塔值为 1.63。该公司的债务与股本比率为 0.64，流动比率为 1.37，速动比率为 1.10。</p>
<p>查尔斯河实验室国际（NYSE:CRL - 获取免费报告）最近于 11 月 5 日发布了季度财报。该医疗研究公司报告本季度每股收益为 2.43 美元，超出分析师一致预期的 2.32 美元，超出幅度为 0.11 美元。查尔斯河实验室国际的净利润率为 -2.07%，股本回报率为 15.78%。该公司本季度的收入为 10 亿美元，而分析师预期为 9.9043 亿美元。在去年同期，该公司每股收益为 2.59 美元。该公司的季度收入同比下降了 0.5%。股票研究分析师预计查尔斯河实验室国际公司今年将发布每股收益 9.36 美元。</p>
<h2>分析师评级变动</h2>
<p>一些研究分析师最近对 CRL 股票发表了看法。瑞穗证券在 12 月 18 日的报告中将查尔斯河实验室国际的目标价从 174.00 美元上调至 200.00 美元，并给予该公司 “中性” 评级。罗伯特·W·贝尔德将查尔斯河实验室国际的股票评级从 “中性” 上调至 “跑赢大盘”，并在 11 月 6 日的报告中将其目标价从 178.00 美元上调至 199.00 美元。华尔街 Zen 在周日的研究报告中将查尔斯河实验室国际的股票评级从 “持有” 上调至 “买入”。巴克莱在 12 月 15 日的报告中将查尔斯河实验室国际的股票目标价从 210.00 美元上调至 215.00 美元，并给予该公司 “增持” 评级。最后，摩根士丹利在 12 月 1 日的报告中为查尔斯河实验室国际的股票设定了 185.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，十一位分析师给予了买入评级，五位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 195.93 美元。</p>
<p><strong>查看我们对 CRL 的最新分析</strong></p>
<h2>关于查尔斯河实验室国际</h2>
<p>（免费报告）</p>
<p>查尔斯河实验室国际公司是制药、生物技术和医疗器械行业领先的研究模型及临床前和临床支持服务提供商。该公司的核心产品包括发现、安全评估、毒理学和病理学服务，以及实验动物和相关诊断的供应。服务涵盖体内和体外测试、生物制剂测试以及对先进疗法的支持，帮助客户加速药物开发，从早期发现到监管提交。</p>
<p>查尔斯河成立于 1947 年，总部位于马萨诸塞州威尔明顿，通过战略投资和收购不断发展，建立了广泛的能力组合。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票，胜过查尔斯河实验室国际</li>
<li>这个无聊的人工智能投资可能每月带来高达 $4,290 的收益</li>
<li>警告：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普的 “美国房地产交易” 解析</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日之前投资 $1,000 到这只股票 [不是 NVDA]</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 到查尔斯河实验室国际吗？</h2>
<p>在你考虑查尔斯河实验室国际之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而查尔斯河实验室国际并不在名单上。</p>
<p>虽然查尔斯河实验室国际目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>在这里查看这五只股票</p>

查尔斯河

<p>Corient Private Wealth LLC 在第二季度将其在查尔斯河实验室国际公司的股份增加了 129.3%，目前持有 11,825 股，价值 1,794,000 美元。其他机构投资者也调整了他们的持股。查尔斯河的股票开盘价为 202.99 美元，市值为 99.9 亿美元。该公司报告第三季度每股收益为 2.43 美元，超出预期。分析师们给出了混合评级，有些分析师上调了他们的目标价格</p>

<p>Corient Private Wealth LLC grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 129.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 11,825 shares of the medical research company's stock after acquiring an additional 6,669 shares during the quarter. Corient Private Wealth LLC's holdings in Charles River Laboratories International were worth $1,794,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Corient Private Wealth LLC 在最近向证券交易委员会提交的 13F 表格中表示，在第二季度将其在查尔斯河实验室国际公司（NYSE:CRL - 免费报告）的股份增加了 129.3%。该机构投资者在本季度额外收购了 6,669 股后，持有该医疗研究公司 11,825 股股票。根据其最近的 SEC 文件，Corient Private Wealth LLC 在查尔斯河实验室国际的持股价值为 1,794,000 美元。</p>
</div><ul>
<li>The 2 Worst Performing S&amp;P 500 Stocks YTD: Buy, Sell, or Avoid?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年迄今表现最差的两只 S&amp;P 500 股票：买入、卖出还是回避？</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of the stock. Exchange Traded Concepts LLC increased its stake in Charles River Laboratories International by 1.3% during the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company's stock valued at $871,000 after purchasing an additional 76 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Charles River Laboratories International by 93.5% during the first quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after buying an additional 86 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Charles River Laboratories International by 1.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company's stock valued at $1,072,000 after acquiring an additional 86 shares during the period. WESCAP Management Group Inc. raised its stake in Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company's stock worth $371,000 after acquiring an additional 89 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D lifted its position in Charles River Laboratories International by 0.7% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 16,829 shares of the medical research company's stock worth $2,553,000 after acquiring an additional 109 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也买卖了该股票的股份。Exchange Traded Concepts LLC 在第二季度将其在查尔斯河实验室国际的股份增加了 1.3%。Exchange Traded Concepts LLC 目前持有 5,742 股该医疗研究公司的股票，价值 871,000 美元，此前在上个季度购买了额外的 76 股。Brooklyn Investment Group 在第一季度将其在查尔斯河实验室国际的持股增加了 93.5%。Brooklyn Investment Group 目前持有 178 股该医疗研究公司的股票，价值 27,000 美元，此前在上个季度购买了额外的 86 股。DekaBank Deutsche Girozentrale 在第二季度将其在查尔斯河实验室国际的持股增加了 1.2%。DekaBank Deutsche Girozentrale 目前持有 7,142 股该医疗研究公司的股票，价值 1,072,000 美元，此前在此期间额外收购了 86 股。WESCAP Management Group Inc. 在第二季度将其在查尔斯河实验室国际的股份增加了 3.8%。WESCAP Management Group Inc. 目前持有 2,443 股该医疗研究公司的股票，价值 371,000 美元，此前在上个季度额外收购了 89 股。最后，新泽西州共同养老金基金 D 在第二季度将其在查尔斯河实验室国际的持股增加了 0.7%。新泽西州共同养老金基金 D 目前持有 16,829 股该医疗研究公司的股票，价值 2,553,000 美元，此前在此期间额外收购了 109 股。当前 98.91% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Charles River Laboratories International Stock Performance</h2>
<div class="lb-trans"><h2>查尔斯河实验室国际股票表现</h2>
</div><p>CRL opened at $202.99 on Wednesday. The firm has a fifty day moving average price of $181.14 and a 200 day moving average price of $166.54. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $204.47. The stock has a market cap of $9.99 billion, a P/E ratio of -130.12, a P/E/G ratio of 7.17 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10.</p>
<div class="lb-trans"><p>CRL 周三开盘价为 202.99 美元。该公司的 50 日移动平均价格为 181.14 美元，200 日移动平均价格为 166.54 美元。查尔斯河实验室国际公司的一年最低价为 91.86 美元，一年最高价为 204.47 美元。该股票的市值为 99.9 亿美元，市盈率为 -130.12，市盈增长比率为 7.17，贝塔值为 1.63。该公司的债务与股本比率为 0.64，流动比率为 1.37，速动比率为 1.10。</p>
</div><p>Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The company had revenue of $1 billion during the quarter, compared to analysts' expectations of $990.43 million. During the same quarter in the previous year, the company earned $2.59 earnings per share. The firm's revenue for the quarter was down .5% on a year-over-year basis. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.</p>
<div class="lb-trans"><p>查尔斯河实验室国际（NYSE:CRL - 获取免费报告）最近于 11 月 5 日发布了季度财报。该医疗研究公司报告本季度每股收益为 2.43 美元，超出分析师一致预期的 2.32 美元，超出幅度为 0.11 美元。查尔斯河实验室国际的净利润率为 -2.07%，股本回报率为 15.78%。该公司本季度的收入为 10 亿美元，而分析师预期为 9.9043 亿美元。在去年同期，该公司每股收益为 2.59 美元。该公司的季度收入同比下降了 0.5%。股票研究分析师预计查尔斯河实验室国际公司今年将发布每股收益 9.36 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts have recently weighed in on CRL shares. Mizuho increased their price objective on Charles River Laboratories International from $174.00 to $200.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, December 18th. Robert W. Baird upgraded shares of Charles River Laboratories International from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price target for the stock from $178.00 to $199.00 in a report on Thursday, November 6th. Wall Street Zen raised shares of Charles River Laboratories International from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday. Barclays upped their price objective on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, December 15th. Finally, Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a report on Monday, December 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $195.93.</p>
<div class="lb-trans"><p>一些研究分析师最近对 CRL 股票发表了看法。瑞穗证券在 12 月 18 日的报告中将查尔斯河实验室国际的目标价从 174.00 美元上调至 200.00 美元，并给予该公司 “中性” 评级。罗伯特·W·贝尔德将查尔斯河实验室国际的股票评级从 “中性” 上调至 “跑赢大盘”，并在 11 月 6 日的报告中将其目标价从 178.00 美元上调至 199.00 美元。华尔街 Zen 在周日的研究报告中将查尔斯河实验室国际的股票评级从 “持有” 上调至 “买入”。巴克莱在 12 月 15 日的报告中将查尔斯河实验室国际的股票目标价从 210.00 美元上调至 215.00 美元，并给予该公司 “增持” 评级。最后，摩根士丹利在 12 月 1 日的报告中为查尔斯河实验室国际的股票设定了 185.00 美元的目标价。一位股票研究分析师对该股票给予了强烈买入评级，十一位分析师给予了买入评级，五位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 195.93 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on CRL</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CRL 的最新分析</strong></p>
</div><h2>About Charles River Laboratories International</h2>
<div class="lb-trans"><h2>关于查尔斯河实验室国际</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.</p>
<div class="lb-trans"><p>查尔斯河实验室国际公司是制药、生物技术和医疗器械行业领先的研究模型及临床前和临床支持服务提供商。该公司的核心产品包括发现、安全评估、毒理学和病理学服务，以及实验动物和相关诊断的供应。服务涵盖体内和体外测试、生物制剂测试以及对先进疗法的支持，帮助客户加速药物开发，从早期发现到监管提交。</p>
</div><p>Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.</p>
<div class="lb-trans"><p>查尔斯河成立于 1947 年，总部位于马萨诸塞州威尔明顿，通过战略投资和收购不断发展，建立了广泛的能力组合。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Charles River Laboratories International</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>ALERT: Drop these 5 stocks before January 2026!</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>A month before the crash</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过查尔斯河实验室国际</li>
<li>这个无聊的人工智能投资可能每月带来高达 $4,290 的收益</li>
<li>警告：在 2026 年 1 月之前抛售这五只股票！</li>
<li>特朗普的 “美国房地产交易” 解析</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日之前投资 $1,000 到这只股票 [不是 NVDA]</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CRL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Charles River Laboratories International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 到查尔斯河实验室国际吗？</h2>
</div><p>Before you consider Charles River Laboratories International, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑查尔斯河实验室国际之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而查尔斯河实验室国际并不在名单上。</p>
</div><p>While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然查尔斯河实验室国际目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Corient Private Wealth LLC 增持了查尔斯河实验室国际公司的股份